Pregnancy outcome in systemic lupus erythematosus complicated by anti-phospholipid antibodies - PubMed (original) (raw)
Pregnancy outcome in systemic lupus erythematosus complicated by anti-phospholipid antibodies
F Mecacci et al. Rheumatology (Oxford). 2009 Mar.
Abstract
Objective: Pregnant women affected by SLE are at high risk of gestational hypertension and pre-eclampsia (32-50%). This risk is particularly elevated if aPLs are dosable. The present study was planned to evaluate maternal-fetal outcomes of different groups of SLE pregnant patients characterized by diverse risk factors: patients affected by APS treated with a combination of low-dose aspirin (LDA) and low-molecular weight heparin (LMWH), nulliparous patients with dosable aPL treated by LMWH and SLE patients with no aPL administered no treatment during pregnancy.
Methods: A retrospective description of maternal and fetal outcomes was made in a total of 62 pregnancies presenting APS in 8 cases (12.9%), aPL in 20 (32.2%) and no aPL in 34 (54.8%).
Results: No statistically significant difference was found comparing fetal and maternal outcomes of the three groups despite differences in SLE activity: SLE aPL-positive pregnancies were associated with a higher incidence of nephritis and chronic hypertension than pregnancies treated for APS or not presenting with the added risk factor. The incidence of pre-eclampsia is 15% in aPL positive, 12.5% in APS and 14.7% in no aPL pregnancies, respectively.
Conclusions: LMWH is rather a possible option of prophylaxis for SLE aPL-positive pregnancies with potential maternal-fetal outcomes similar to aPL-negative patients or to standard treated APS.
Similar articles
- The HELLP syndrome in the antiphospholipid syndrome: retrospective study of 16 cases in 15 women.
Le Thi Thuong D, Tieulié N, Costedoat N, Andreu MR, Wechsler B, Vauthier-Brouzes D, Aumaître O, Piette JC. Le Thi Thuong D, et al. Ann Rheum Dis. 2005 Feb;64(2):273-8. doi: 10.1136/ard.2003.019000. Ann Rheum Dis. 2005. PMID: 15647435 Free PMC article. Review. - Longitudinal study of antinuclear and anticardiolipin antibodies in pregnant women with systemic lupus erythematosus and antiphospholipid syndrome.
Salazar-Páramo M, Jara LJ, Ramos A, Barile L, Machado G, García-De La Torre I. Salazar-Páramo M, et al. Rheumatol Int. 2002 Aug;22(4):142-7. doi: 10.1007/s00296-002-0207-x. Epub 2002 Jun 19. Rheumatol Int. 2002. PMID: 12172952 - Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study.
Ruffatti A, Tonello M, Visentin MS, Bontadi A, Hoxha A, De Carolis S, Botta A, Salvi S, Nuzzo M, Rovere-Querini P, Canti V, Mosca M, Mitic G, Bertero MT, Pengo V, Boffa MC, Tincani A. Ruffatti A, et al. Rheumatology (Oxford). 2011 Sep;50(9):1684-9. doi: 10.1093/rheumatology/ker139. Epub 2011 Jun 7. Rheumatology (Oxford). 2011. PMID: 21652586 - Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome.
Tektonidou MG, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos PG, Moutsopoulos HM. Tektonidou MG, et al. Arthritis Rheum. 2004 Aug;50(8):2569-79. doi: 10.1002/art.20433. Arthritis Rheum. 2004. PMID: 15334471 - Management of thrombosis in antiphospholipid syndrome and systemic lupus erythematosus in pregnancy.
Ruiz-Irastorza G, Khamashta MA. Ruiz-Irastorza G, et al. Ann N Y Acad Sci. 2005 Jun;1051:606-12. doi: 10.1196/annals.1361.105. Ann N Y Acad Sci. 2005. PMID: 16127001 Review.
Cited by
- Adverse Impact of Systemic Lupus Erythematosus on Pregnancy Outcomes: A Saudi Arabia Retrospective Multi-Center Study.
Al Rayes H, AlOudah N, Alsolaimani R, Alharthi A, Attar M, Daghasi H, Albeity A, Afifi AM, AlQahtani A, Alkaff A, Alkhamesi SM, Elnady B. Al Rayes H, et al. Open Access Rheumatol. 2024 Feb 1;16:31-41. doi: 10.2147/OARRR.S448186. eCollection 2024. Open Access Rheumatol. 2024. PMID: 38322608 Free PMC article. - A Comprehensive Literature Review on Managing Systemic Lupus Erythematosus: Addressing Cardiovascular Disease Risk in Females and Its Autoimmune Disease Associations.
Dar S, Koirala S, Khan A, Bellary MD, Patel AV, Mathew B, Singh R, Baigam N, Razzaq W, Abdin ZU, Khawaja UA. Dar S, et al. Cureus. 2023 Aug 18;15(8):e43725. doi: 10.7759/cureus.43725. eCollection 2023 Aug. Cureus. 2023. PMID: 37727166 Free PMC article. Review. - British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids.
Russell MD, Dey M, Flint J, Davie P, Allen A, Crossley A, Frishman M, Gayed M, Hodson K, Khamashta M, Moore L, Panchal S, Piper M, Reid C, Saxby K, Schreiber K, Senvar N, Tosounidou S, van de Venne M, Warburton L, Williams D, Yee CS, Gordon C, Giles I; BSR Standards, Audit and Guidelines Working Group. Russell MD, et al. Rheumatology (Oxford). 2023 Apr 3;62(4):e48-e88. doi: 10.1093/rheumatology/keac551. Rheumatology (Oxford). 2023. PMID: 36318966 Free PMC article. No abstract available. - Thrombosis and Anticoagulation Therapy in Systemic Lupus Erythematosus.
Yuan W, Guan F. Yuan W, et al. Autoimmune Dis. 2022 Jun 27;2022:3208037. doi: 10.1155/2022/3208037. eCollection 2022. Autoimmune Dis. 2022. PMID: 35795725 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous